Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2001 September;26(3) > Minerva Endocrinologica 2001 September;26(3):119-22

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

  NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES: SOMATOSTATIN ANALOGS. Part I


Minerva Endocrinologica 2001 September;26(3):119-22

language: Italian

Drugs interfering with somatostatin receptors

Berrino L., Rossi S., Formato P., Vitelli M.


PDF  


The use of drugs interfering with somatostatin receptors (ssR) is now consolidated practice in diagnostics and therapy, stimulating the development of new and more efficient molecules offering improved pharmacodynamics. Over the years, we have passed from the use of native somatostatin to ''mini-somatostatin'' and then octapeptides, above all octreotide. Subsequently, peptides were synthesized with specific affinities for a single receptorial subtype, like compound BIM23268 and compound CH275. More recently, somatostatin analogs were synthesized with a non-peptide structure.
Another important aspect in the history of sst analogs is represented by the development of new pharmaceutical formulas for these drugs in order to improve patient compliance by reducing dose frequency.

top of page

Publication History

Cite this article as

Corresponding author e-mail